Coultreon’s $125M Bet Proves the Real Alpha in Biotech Is Knowing Which Shipwrecks Are Worth Salvaging
Coultreon Biopharma raised $125M Series A for rescued Galapagos oncology assets — and the investor syndicate tells you exactly...
series A funding
Europe’s Biotech Execution Gap Demands Capital Reform and Regulatory Harmony
At BIO-Europe Spring 2026 in Lisbon, investors and pharma executives diagnosed Europe's biotech bottleneck not as a science deficit...